Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Regeneron

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Regeneron's Japan sales performance.

regeneron

After Lucentis setback, Novartis trumpets data on follow-up drug

After Lucentis setback, Novartis trumpets data on follow-up drug

The experimental therapy – called brolucizumab (RTH258) – showed its was superior to a Bayer and Regeneron’s Eylea (aflibercept) in tackling a key disease activity marker in age-related macular degeneration (AMD),

FDA awards another non-opioid pain drug breakthrough status

FDA awards another non-opioid pain drug breakthrough status Other non-opioid treatments in the late-stage pipeline are Pfizer and Lilly’s tanezumab and Regeneron and Teva’s fasinumab..

AZ, Amgen’s first-in-class asthma drug gets breakthrough status

AZ, Amgen’s first-in-class asthma drug gets breakthrough status Regeneron’s new candidate Dupixent (dupilumab), an IL-4 and IL-13 inhibitor that is already approved for atopic dermatitis.

Regeneron and Teva close gap on rivals with NGF pain drug

Regeneron and Teva close gap on rivals with NGF pain drug Regeneron and Teva’s nerve growth factor (NGF) inhibitor fasinumab hit the mark in a phase III osteoarthritis trial, potentially setting up a race to the finish line in the ... Earlier this year, Regeneron also revealed it had halted a high-dose arm in

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics